APC Bio Innovations Inc.

APC Bio Innovations Inc., doing business as Apcbio, is a woman-owned small business based in Frederick, Maryland that develops recombinant protein therapeutics for federal biomedical research, operating as a prime recipient on National Institutes of Health grants and as a sub-recipient on collaborative research awards. Apcbio is structured as a Subchapter S corporation and competes under the WOSB designation across its federal footprint.

Apcbio's capability portfolio centers on the development, production, and characterization of recombinant human proteins for pulmonary and immunological applications. The vendor's recent prime grant work includes a National Heart Lung and Blood Institute project grant awarded August 5, 2023 (ultimate completion August 4, 2025) focused on recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction in lung transplant patients; that award addresses optimization of drug potency and potency-enhanced formulations to improve therapeutic delivery efficiency in patients with a median post-transplant survival of six years. An earlier NHLBI project grant from September 1, 2021 (completed May 31, 2024) investigated the role of secretoglobin 1A1 protein in COVID-19-induced thrombosis, examining both in vitro coagulation effects and patient-level correlations between SCGB1A1 depletion and thrombotic complications.

The vendor's sub-award work includes a Washington University-led federal grant (awarded August 26, 2025) in which Apcbio produces and supplies recombinant human club cell protein for Aim 2 studies on CD8+ T-cell regulation in chronic lung allograft dysfunction, providing quality control data on protein stability and oxidation and participating in data interpretation and manuscript preparation.

Customer concentration is narrow — two NIH institutes (the National Heart Lung and Blood Institute with two awards and the National Institute of Allergy and Infectious Diseases with one) account for 100% of recent awards. Combined dollars obligated across all three awards total $1.3 million. Activity is sparse, with one award per year across 2021, 2023, and 2025, indicating a small federal research footprint focused on pulmonary protein biology and therapeutics.

APCBio is a molecular and cell biology lab with protein therapeutic and vaccine development capabilities, including upstream and downstream processing and process development (microbial fermentation and protein purification, analytical method development, formulation and stability testing, GLP-enabled for analytical methods such as HPLC, ELISA, data imaging, biological sample analysis, cell culture, biological activity/potency assay development, cloning and expression, filtration, chromatography, scale-up, etc.